In Brazil, two suspected cases of Ebola were recently ruled out after both patients tested negative for the virus. The individuals were monitored in São Paulo and Rio de Janeiro after returning from the Democratic Republic of Congo and Uganda, respectively. The man in São Paulo, a 37-year-old who had traveled to the DR Congo, exhibited symptoms such as fever but had already tested positive for meningitis. Meanwhile, the other patient, a Belgian man in Rio de Janeiro who had traveled to Uganda, showed viral symptoms including cough, chills, and diarrhea, but tested positive for malaria instead of Ebola. Local health authorities confirmed that if these cases had been positive, they would have marked the first Ebola infections outside of Africa since the outbreak began in the DR Congo. The current outbreak in the DR Congo has resulted in over 1,000 suspected cases and at least 246 deaths, primarily concentrated in the Ituri, North Kivu, and South Kivu provinces. Uganda has also reported nine confirmed cases and one death related to the outbreak. The strain of Ebola responsible for the current outbreak is known as Bundibugyo, which is particularly concerning as it has no proven vaccine and has a mortality rate of about one-third for those infected. In response to this outbreak, three new vaccines are being developed by organizations including the International Aids Vaccine Initiative (IAVI), the University of Oxford, and the pharmaceutical company Moderna. The development of these vaccines is crucial, as Ebola viruses typically infect animals, especially fruit bats, and can spread to humans through direct contact with bodily fluids of infected individuals. The swift response from Brazilian health authorities in monitoring and testing these patients highlights the importance of vigilance in the face of potential outbreaks. The negative test results provide some relief, but the ongoing situation in the DR Congo and Uganda remains a significant public health concern, emphasizing the need for continued research and development of effective vaccines and treatments for Ebola.